Foscarnet and ganciclovir combination therapy for CMV disease in HIV-infected patients.
An open prospective trial of combined ganciclovir and foscarnet therapy for 3 weeks was initiated in 14 episodes of severe CMV-disease in 13 HIV-infected patients (all CDC class IV, age 30-42, median 34 years, CD4+ cell count 0-80, median 10/microliters). In seven episodes of gastrointestinal disease (five colitis, two esophagitis) remission of symptoms and mucosal changes was achieved in five. In seven episodes of retinitis, scarring was achieved in six. Renal toxicity was seen in two patients, moderate hematologic toxicity in eight patients. Overall efficacy was comparable to monotherapy; no new toxicities were seen with the combination of these two drugs.
Salzberger
B
B
Medizinische Klinik I, Universitätsklinik Köln, Germany.
Stoehr
A
A
Heise
W
W
Fätkenheuer
G
G
Schwenk
A
A
Franzen
C
C
Cornely
O
O
Schrappe
M
M
D017088:AIDS-Related Opportunistic Infections / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D000328:Adult; D003092:Colitis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D003586:Cytomegalovirus Infections / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D017726:Cytomegalovirus Retinitis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D017245:Foscarnet / Q000627:therapeutic use*; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome
D017245:Foscarnet; D015774:Ganciclovir